AstraZeneca to send direct mail for Toprol-XL

Share this article:
AstraZeneca will send out direct-mail communications as part of a larger campaign for its hypertension drug, Toprol-XL, following reports of name confusion between the treatment and other Rx brands. The overall program launch's audience will include pharmacists and pharmacy technicians, physicians, physician assistants, nurse practitioners, nurses and patients.
Share this article:
close

Next Article in News

Email Newsletters

More in News

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union

Rep access continues to shrink

Rep access continues to shrink

Sales reps are experiencing even more limited physician access, according to a report by Chicago consultancy ZS Associates.

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.